

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 February 2003 (27.02.2003)

PCT

(10) International Publication Number
WO 03/015837 A1

(51) International Patent Classification⁷: **A61L 27/50**,
27/48

(ZA). **THERON-PETERS, Jacobus**; 11 Lourensz Street,
Brandwacht, Stellenbosch, 8001 Cape Town (ZA).

(21) International Application Number: **PCT/US02/27113**

(74) Agents: **COLLIER, Kenneth, J.** et al.; 710 Medtronic
Parkway NE, Minneapolis, MN 55432-5601 (US).

(22) International Filing Date: 18 August 2002 (18.08.2002)

(81) Designated State (*national*): **ZA**.

(25) Filing Language: English

(84) Designated States (*regional*): European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,
LU, MC, NL, PT, SE, SK, TR).

(26) Publication Language: English

(30) Priority Data:
60/313,075 17 August 2001 (17.08.2001) US

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(71) Applicant: **MEDTRONIC, INC.** [US/US]; LC 340, 710
Medtronic Parkway, Minneapolis, MN 55432 (US).

(72) Inventors: **ZILLA, Peter, P.**; 14 Dal Road, Camps Bay,
8001 Cape town (ZA). **BEZUIDENHOUT, Dean**; 3 Capri
Court, Davenport Road, Vredenhoeck, 8001 Cape Town

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: **POROUS VASCULAR GRAFT PROSTHESES WITH LUMINAL SEALING LAYER**

(57) Abstract: A vascular graft prosthesis having ingrowth-permissive luminal wall features with a thin film or layer of sealant-like material placed at a luminal wall location to promote improved transmural tissue growth and healing.

ZM. USSN. 10/132,754

WO 03/015837 A1

BEST AVAILABLE COPY

POROUS VASCULAR GRAFT PROSTHESES WITH LUMINAL SEALING LAYER

RELATED APPLICATION

This application claims priority to provisional U.S. Application Ser. No. 60/313,075, filed August 17, 2001.

FIELD OF THE INVENTION

This invention relates to improved structures for vascular graft prostheses.

BACKGROUND OF THE INVENTION

A range of vascular grafts are utilized within the medical arts fields, but often such grafts do not permit sufficient healing due to many reasons. In particular, small diameter conventional vascular grafts do not permit sufficient tissue ingrowth or transmural endothelialization that would allow for proper healing and satisfactory long-term outcomes. Larger bore grafts often are too stiff and do not have proper ingrowth of surrounding tissue. Various approaches have been attempted to overcome these deficiencies in the prior art, with relative lack of success. This invention is designed to provide solutions to these serious and long misunderstood problems.

BRIEF SUMMARY OF THE INVENTION

A vascular graft prosthesis has a polymeric tubular structure. The structure has a porous wall with interstices arranged to permit transmural ingrowth of tissue substantially through the full thickness of the wall. A thin film or layer of sealant material is on a portion of the wall forming a luminal wall surface which promotes rather than inhibits transmural tissue growth.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a sectional schematic view of a segment of a hybrid graft model illustrating fibrin buildup.

Figure 2 is a sectional schematic view of a segment of an ePTFE graft model illustrating fibrin buildup.

Figure 3 is a sectional schematic view of a segment of a polyurethane graft model illustrating fibrin buildup.

Figure 4 is a sectional schematic view of a segment of a polyethylene terephthalate (e.g. Dacron) graft model illustrating fibrin buildup.

Figure 5 is a sectional schematic view of a test segment of a graft model.

Figure 6 is a sectional schematic view of a segment of a hybrid graft model illustrating the lack of fibrin buildup due to a first embodiment lumenal sealant.

Figure 7 is a sectional schematic view of a segment of an ePTFE graft model illustrating a first embodiment lumenal sealant.

Figure 8 is a sectional schematic view of a segment of a polyurethane graft model illustrating a first embodiment lumenal sealant.

Figure 9 is a sectional schematic view of a segment of a polyethylene terephthalate (e.g. Dacron) graft model illustrating a first embodiment lumenal sealant.

Figure 10 is an exemplary unit cell of a porous foam-type material of a graft structure.

Figure 11 is a sectional schematic view of a segment of a graft model illustrating a second embodiment lumenal sealant.

Figure 12 is a sectional schematic view of a segment of a graft model illustrating a third embodiment lumenal sealant.

Figure 13 is a sectional schematic view of a segment of a graft model illustrating a third embodiment lumenal sealant.

DETAILED DESCRIPTION OF THE INVENTION

Various coatings and graft-related surface applications are known, but none have been utilized or specifically designed according to the technology disclosed herein, nor have any been functionally appropriate for achieving the excellent results to overcome the problems of the prior art. Conventional vascular graft prostheses do not permit sufficient tissue ingrowth or transmural endothelialization that would allow for proper healing and satisfactory long-term outcomes. This is partly due to a failure of past designers to recognize certain mechanisms and partly due to inadequate materials to assemble or manufacture the proper structures. For example, a 30 μ m expanded polytetrafluoroethylene (ePTFE) graft has been shown to not support full transmural

healing due to the fact that the capillaries (10-15 μ m in diameter), the smallest vessels required to sustain tissue in the graft wall, simply are not able to grow in to the full extent of the wall. This is due to the tight packing of intermodular fibrils. Thus, although the intermodular distance may be 30 μ m, the actual ingrowth dimensions are much lower (probably in the range of 5-10 μ m). In addition, the lack of defined channels (interconnections between "pores") of sufficient porosity results in the "tapering down" of ingrowth spaces as one progresses into the wall. A similar analysis may be made for tightly woven fabric grafts (such as, for example, the material known as Polyethylene terephthalate (also referred to herein by its trade name "Dacron")). Further, the similar problem exists in foam type structures described in the prior art, such as those fabricated from polyurethane. The definition of these polyurethane graft pore dimensions is rather difficult, as the pores are irregular in shape and size, and generally have poor interconnectivity. In addition many of them have impermeable (at least to tissue) skins on either or both the abluminal and luminal sides.

Consequently, the attendant space restrictions within the structures of artificial grafts create a hostile environment for desired tissue ingrowth. These space restrictions are caused by two main factors. The first factor is the physical structure of the graft wall material. Typically, there is inadequate spacing for capillaries to grow transmurally into the graft beyond only one outer portion. The second factor is the filling of the inner luminal portion of the graft wall by either blood products or artificial sealant materials. In either case, the clogging of the inner portion of the wall structure creates a growth-prohibitive environment that prevents desired healing.

Two types of angiogenesis are desirable for spontaneously healing of vascular grafts. A pure capillary ingrowth with the goal of surface endothelialization (with a space requirement of greater than about 10 μ in continuity) is one type. A second type is arteriole ingrowth with a goal of surface endothelialization plus arterialization of the prosthetic vessel wall (with a space requirement of about 23 μ in continuity). In addition to the arterialization of capillary walls, the population of the pores by smooth muscle cells and other desirable cell and extracellular matrix tissues is required for long-term healing and other performance characteristics, such as flexibility and compliance.

Although synthetic grafts have been shown to endothelialize by transanastomotic outgrowth in some animal models, notably canine, it is well known that this type of

outgrowth in humans is limited to 1-2cm (peripheral graft length up to 60cm). The goal of Applicants is, therefore, to achieve transmural ingrowth of endothelial cells and subsequent confluent endothelialization of the graft lumen.

This invention discloses short- and long-term strategies to overcome this healing problem, for both large and small diameter grafts. One short-term strategy includes use of a permanent sealant or film on a very high porosity graft material, such as highly porous expanded polytetrafluoroethylene (ePTFE). One long-term solution includes use of a temporary sealant on porous polyurethane grafts with angiopermissive porosity. It is recognized that other combinations of short-term and long-term solutions are contemplated and possible within this invention. Overall, however, the lack of healing in commercial grafts can be ascribed to the insufficient size of the ingrowth spaces. Due to the irregular structure of the pores (between the nodes and internodular fibers), the available ingrowth spaces rapidly narrow down to sub-arteriole dimensions. It is known that increasing the internodal distances in grafts to 45, 60 and 90 μ m respectively, has been attempted, but without significant improvement in healing response. Further, various "foam type" experimental prostheses have also been developed from elastomeric materials in order to increase the ingrowth spaces and attain compliance matching with natural vessels. These prostheses also failed to show sufficient healing due to a variety of factors, including small pore sizes, limited interconnectivity between pores and permanent (impermeable) abluminal and/or luminal skins. Also, various sealants have been used in vascular prostheses, and possibly without appreciating the adverse effects these sealants have on the healing process. These include, for example, hemostatic impregnation of the graft wall with collagen, fibrin or gelatin in order to prevent excessive blood flow through the wall during implantation, and coating of the surfaces of grafts with elastomers or growth inhibitors, etc., for reasons other than to improve transmural healing and in manners adverse to healing.

Conventional ePTFE and Polyethylene terephthalate (e.g. Dacron) prosthetic vascular grafts do not permit vessel ingrowth from the surrounding tissue due to too narrow or discontinuous ingrowth spaces. However, novel polyurethane prostheses, including those of

Applicants, do not have such limitations, as their well-defined porosity and large pore size allow for the uninterrupted ingrowth of tissue. For example, see U.S. Patent Application

No. 09/434,649; International Patent Applications PCT US97/27629 and WO 01/05333, all of which are commonly assigned to the Assignee of the present application.

Although these high porosity polyurethane grafts, as well as ePTFE grafts with very high internodular distances (100-150 μ m), and high porosity Polyethylene terephthalate (e.g. Dacron) or similar grafts, may all allow for the improved ingrowth of tissue and cells, the level of healing that is desired throughout the graft wall is not observed. This has been shown to be due to the chronic deposition of impenetrable blood products, such as fibrin, onto/into the luminal surface portion, thereby limiting ingrowth and healing to only the abluminal or outer portions of the graft wall.

Accordingly, achievement of spontaneous healing of ePTFE, polyurethane, or other vascular prostheses by providing very high, angiopermissive porosities (for example, $\pm 150 \mu$ m IND/pore size) and a permanent or degradable luminal film to limit or control fibrin deposition and compaction is one goal.

As shown in Figures 1-4, prior research and design failed to properly recognize and overcome the deposition and compaction problem created by the buildup of hostile and impenetrable fibrin or other blood products on luminal surfaces and luminal portions. In Figures 1-4, graft model 12 comprises any of a plurality of materials, including for example, ePTFE 15, polyurethane 19, or Polyethylene terephthalate (e.g. Dacron) 22. As shown, these materials form a luminal wall 28 (which is shown having multiple different material constructions for illustration only) having an abluminal outer portion 33, outer surface 36, luminal inner portion 40 and luminal surface 44. In normal grafts of these or other materials there is a flow of blood 50 therethrough, which also forms a natural deposit of blood products 53, e.g., fibrin or other products. This blood product formation creates a barrier effect which prevents abluminal and transmural tissue ingrowth. The barrier effect functionally extends from within the vascular (graft) lumen out into the luminal wall to a substantial distance (as shown by arrows 68), in some instances greater than 50% of a wall thickness, causing serious degradation of healing and prevention of healthy ingrowth of various tissue types. Failure to heal may lead to rejection, stiffness and even malfunctioning.

Efforts to determine the best technique to prevent this barrier included use of a hybrid test model graft 120, as shown in Figure 5. This model graft was designed to prevent transanastomotic outgrowth (as shown at pannus growth portions 124 and arrows

T₁) from a centrally located graft portion test segment 127, and thereby ensure that any endothelium observed on the test segment originated from transmural ingrowth only. In this example, model graft 120 uses isolating segments 133 of low porosity (30 μ m) ePTFE around a high porosity material such as, for example, high porosity ePTFE, Polyethylene terephthalate (e.g. Dacron) or high porosity polyurethane to form a graft portion test segment 127. A sealant or film material 149 is placed between isolating and test segments to prevent tissue ingrowth between the two graft segments. This test demonstrated that the film material prevented or facilitated the prevention of unwanted growth via any anastomotic approach (arrows T₁) or transmural approach (T₂), while promoting the desired transmural ingrowth through the test segment as shown by arrows G. This test also demonstrated the inability of tissue to grow transmurally through a low porosity material (T₂).

Applicants have discovered short- and long-term strategies, methods, and structures to overcome the problem of barriers to abluminal tissue growth, i.e. the desired growth from outside the graft wall toward the lumen. In particular, in various embodiments, Applicants have realized that a thin skin or film of material may be applied within the inner luminal portion 40 or 44 of an ingrowth-permissive synthetic graft with very advantageous results. Figures 6-9 illustrate sections of a schematic model graft 75 formed of any of the graft materials noted above, and further described below. In Figure 6, model graft 75 (which is shown having multiple different material constructions for illustration only) illustrates two different types of graft wall material, ePTFE 81 and polyurethane 84- although other materials are possible if the configuration of the material allows for transmural tissue ingrowth. A thin film of permanent or degradable sealant material 88 is placed on a luminal portion 90, which may include the luminal surface 94, of the graft wall 96. This placement of film material 88 must functionally prevent the buildup of blood products, e.g. fibrin, without clogging the pores or other interstitial growth spaces within the graft wall structure. This promotes the transmural ingrowth of tissue ablumenally to the inner luminal portion of the graft, as shown by arrows 97, which promotes improved healing and greater compliance and patency of the graft. Figures 7, 8, and 9 show graft walls 96 made of either high porosity ePTFE 81 (Figure 7), high porosity polyurethane 84 (Figure 8), or Polyethylene terephthalate (e.g. Dacron) 99 (Figure 9).

A preferred ePTFE material includes pore sizes having an internodular distance (IND) of greater than about 60 μm and more preferably about 60 to about 200 μm . A preferred porous foam-type of material includes a polyurethane material having spheroid interconnected pores formed as unit cells resembling dodecahedra, although various shapes may provide the desired characteristics. Figure 10 shows a representation of one embodiment of a 50-250 μm diameter pore 100 having 20-150 μm diameter interconnecting windows 105, as shown by diameter line 108. A preferred Polyethylene terephthalate (e.g. Dacron), or other material, should be constructed (i.e. knitted, felt, or other technique) so that the porosity between fibers permits transmural growth substantially through to an inner luminal portion. The wall thickness of grafts made according to this invention may be about 0.2-2 mm, with a preferred range of about 0.3-0.7 mm, and an overall graft diameter of between about 2-25 mm. The thickness of a solid sealant or film material may be in the range of 10-200 μm , with a preferred range of thickness of about 20-50 μm . Examples of suitable graft materials and constructions are shown in co-pending and commonly owned patent applications: U.S. Serial No. 09/434,649; International Patent Applications PCT US97/27629 and WO 01/05333, each of which is incorporated by reference for such teaching.

The film material should span each pore of the surface of the graft wall luminal portion, or at a selected depth--rather than filling each pore it contacts. For example, the film should function as if it were a thin piece of paper laying atop a sponge to prevent material penetration into the sponge pores below the paper. In a similar manner the film of sealant material acts as a spanning film rather than a filling sealant, so as to separate the blood from the tissue with as little thickness as possible or desired.

Figure 11 shows another embodiment of improved graft prostheses 121 combining angio-permissive graft wall material 125 with a preferred film 129 at a luminal portion of the wall structure, as described herein. Another material, referred to herein as an additional porous layer 134, provides either a porous structure or a surface having increased roughness as compared to film material 129. Layer 134 is designed to improve graft patency by creating a more anti-thrombogenic effect within the lumen 142. Tissue ingrowth lines 150 illustrate the depth to which transmural ingrowth occurs when this combination of ingrowth-permissive wall material and a preferred film is utilized.

Figure 12 shows a graft prosthesis 161 formed substantially similar to that of Figure 11, except that wall structure 125 has a film material 129 that is covered or substantially coated with a thin anti-thrombotic surface 167, rather than a thicker porous structure as shown by structure 134 in Figure 11.

As noted herein, the sealant or film material may be a permanent, semi-permanent or intentionally degradable material. For example, in a large aortic-size graft prosthesis, it may be desirable to have a permanent film or a film having a degree of permanence which extends over considerable time in order to permit rapid and continuous muscle-like tissue ingrowth transmurally through the graft. For such prostheses, particularly that where flexibility is quite important to functionality, a permanent film might best facilitate such rapid transmural tissue ingrowth. However, in that or other applications, it may also be desirable to permit full tissue penetration transmurally into the luminal portion of the graft. This may require a film having various thicknesses or a thickness designed to permit tissue penetration, transmurally, after a specified length of time. Another way of achieving this goal is to provide a film having a structure similar to that represented in Figure 13. In this figure, graft prosthesis 183 comprises a graft wall material 186 which is an ingrowth-permissive material, such as those mentioned herein, and which has a film 190 which defines regions 194 of degradation over time which allow for the degradation of these areas to form communications between the abluminal and luminal surfaces and thereby promote full transmural ingrowth by tissue. It is recognized that regions 194 are shown in a representative fashion only for illustration of this concept, and may comprise various patterns or area configurations. Such regions 194 may also prevent the sloughing off of large pieces of degradable material as it naturally degrades over the desired time. Of course, preferred degradation times will vary according to the recipient of the graft prosthesis and the type of material within the graft.

The material which forms the film of Applicants is preferably a polymeric film which is deposited in as thin a structure as possible, but strong enough to withstand the rigors of the biological system within which the graft is placed. The film is designed to obstruct rather than clog the pores of the luminal portion of the graft, and by not necessarily penetrating the pores the film permits rapid and effective transmural ingrowth of tissue to promote healing throughout the width of the graft wall. If either the graft wall is made of ingrowth-prohibitive material or the luminal portion of the graft wall is sealed

off or clogged by either a sealant material (unlike that preferably described herein as a film) or by blood products such as compacted fibrin or the like, then the graft prosthesis will fail to demonstrate the advantageous results and characteristics as described by Applicants. Alternatively, use of a graft wall material which is ingrowth-permissive so that a complete transgression from the outer wall into the lumen of the graft is permitted for capillaries, and the type of film described herein is provided at a luminal portion to facilitate and encourage rapid ingrowth of the capillaries and tissue transmurally, then the combination will result in improved outcomes and higher acceptance of the graft by the recipient or host body.

The permanent or semi-permanent sealants or films of this invention include medical grade polyurethanes, such as for example those known by the names Pellethane, M48, Elast-Eon, Bionate, or other medical grade polyurethanes marketed under various trade names. The method of application of the material includes application of the polymer solution to a luminal portion or surface and then solidification of the polymer by evaporation and/or precipitation. Anti-thrombogenicity may be enhanced by the covalent immobilization of heparin onto the luminal surface after placement of the material.

Example 1

A 150 μm polyurethane and 150 μm internodular diameter ePTFE with plus or minus ± 50 μm polyurethane luminal film skin was provided. Acrylic acid/acrylamide hydrogel and ethylene diamine (EDA) bridge and a periodate oxidized heparin was provided as well. The results indicated an improvement in tissue (including capillaries and arterioles) ingrowth when compared to the ingrowth obtained in similar prostheses without the luminal skin. In particular, the ingrowing vessels occupied the full extent of the graft wall thickness (up to the abluminal side of the luminal film) of grafts provided with a luminal film. When the luminal film was absent, a thick band of compacted fibrin (and other blood constituents) was observed in the luminal third of the graft wall. This fibrin layer impeded and restricted the further ingrowth of tissue, and thereby limited the healing to the outer two-thirds of the graft wall.

Medical grade polysiloxanes, for example that known as PDMS (trade name NuSil) or other branded medical grade polysiloxanes are also useful as a film. Application of the monomer or prepolymer to the luminal portion or surface is accomplished. Then,

solidification of the polymer by reaction with an initiator occurs. Silicone films are permeable to oxidation and carbon dioxide and may be used (when compared to essentially oxygen-impermeable materials e.g. polyurethanes) to determine the effect of hypoxia on the healing of sub-sealant regions. Hypoxia is one of the possible mechanisms which are involved with the advancements of this invention.

The degradable films or sealants discussed herein include degradable polyurethanes, polyethylene oxide-poly(lactic acid) copolymers and degradable hydrogels. Although most polyurethanes are designed to be biostable, i.e. to resist chemical degradation in vivo, there are instances for this application where biodegradability may be desired. One class of such materials include the polyesters (polyglycolic acid, polylactic acid, polycaprolactone, polyhydroxybutyrate, polyorthoesters, etc.), polyanhydrides (poly(sebacic acid-hexadecanoic acid anhydride)), and polyiminocarbonates. Another class of degradable materials includes synthetic hydrogels, which may be simply non-degradable hydrogel monomers incorporating degradable sites in their chains and/or using degradable crosslinkers. One example includes synthetic hydrogels (such as polyethyleneglycol, etc.) that are cross-linked by hydrolytically or enzymatically cleavable compounds in such a way that cleavage of the crosslinker results in the degradation of the crosslinked polymer.

Another class of biodegradable polymers includes the biologically derived hydrogels such as polyamino acids and polysaccharides. Synthetic hydrogels include a number of other water soluble polymers which may be used to form hydrogel films by a wide range of crosslinking reactions. These materials include polyethyleneglycol (PEG), polyvinyl alcohol

(PVAL), polyvinyl pyrrolidone (PVP), polyethyleneimine (PEI), polyhydroxyethyl methacrylate (PHEMA) family, polyacrylic acid (Paac), polyacrylamide (Paam), etc. Crosslinking may be effected by: inclusion of a di or multi-vinyl compounds during polymerization and reaction of di-or multifunctional compounds with side groups of preformed linear polymers. Another class of degradable polymers are of biologic origin. When they occur in their hydrated insoluble state, these materials may also be classified as hydrogels. Both carbohydrates (hyaluronic acid, cellulose, alginates) and proteins (collagen, gelatin) may be immobilized as a hydrogel films on the surface of grafts by crosslinking with a variety of compounds.

It is, therefore, a goal of Applicants to achieve spontaneous healing and luminal endothelialization of ePTFE, polyurethane, Polyethylene terephthalate (e.g. Dacron) or other vascular prostheses by providing very high angiopermissive porosities ($\pm 150\mu\text{m}$ IND/pore size) and permanent or degradable luminal portion films to better control the deposition and compaction of blood products. The film would initially inhibit, prevent, or control the deposition of impenetrable fibrin or other products in the pores of the wall structure, thereby allowing uninterrupted tissue ingrowth from the abluminal surface. Any degradable film material would be dissolved or otherwise eliminated through biologic action, while allowing the population and proper healing of the luminal surface by transmural tissue ingrowth. In addition to the concepts disclosed above, Applicants believe that this novel and non-obvious luminal sealant or film, having possible degradation features designed therein, provides a temporary shield against plasma insituization as well as a temporary modality to create controlled hypoxia during the healing process, thus permitting proper penetration of desired tissues in the desired manner, and obviating creation of undesirable barriers to such healing.

No other recognition of such a problem and solutions is known by Applicants, nor have Applicants noted the recognition by any other of the underlying cause of the failure of these grafts to properly heal due to the buildup from the luminal surface creating a hostile environment for adequate transmural tissue ingrowth.

WE CLAIM:

1. A vascular graft prosthesis having a polymeric tubular structure with a porous wall characterized by interstices arranged in the wall to permit transmural ingrowth of tissue substantially through the full thickness of the wall, and a layer of sealant material on a portion of the wall forming a luminal wall surface which reduces the buildup of natural blood products at and adjacent to the luminal wall surface and facilitates transmural growth of tissue.
2. The vascular graft prosthesis of claim 1, characterized in that the sealant material has a degradable property so that the material will degrade in a predetermined manner or time.
3. The vascular graft prosthesis of claim 1, characterized by the sealant material being selected from the group consisting of polyurethane, a polysiloxane polymer, segmented polyurethane, lactic/glycolic polymers, polyethylene glycol-poly(lactic acid) copolymer, synthetically derived hydrogels, polyethylene glycol hydrogels, and biologically derived hydrogels.
4. The vascular graft prosthesis of claim 1, characterized in that the polymeric tubular structure wall material is selected from the group consisting of polyurethane, expanded polytetrafluoroethylene, and Polyethylene terephthalate (Dacron).
5. The vascular graft prosthesis of claim 1, wherein the tubular structure comprises interconnected shaped pores having an internodular distance of greater than about 60 μm .
6. The vascular graft prosthesis of claim 1, characterized in that the tubular structure comprises interconnected shaped pores having diameters of greater than about 60 μm and less than about 200 μm .
7. The vascular graft prosthesis of claim 1, characterized in that the tubular structure comprises a polymer structure having a wall, and interconnecting shaped pores in the wall; wherein porosity is optimized to maximize cellular in-growth.

8. The vascular graft prosthesis of claim 1, characterized in that the tubular structure has a wall thickness in the range of 0.2-2 mm.
9. The vascular graft prosthesis of claim 6, characterized in that the tubular structure has pores with an average diameter in a range of 100-200 μm .
10. The vascular graft prosthesis of claim 1, characterized in that the tubular structure has pores with an average diameter in a range of 0.1 – 3.0 mm, allowing for un-interrupted tissue growth; and wherein the overall graft diameter is between about 2-25 mm.
11. The vascular graft prosthesis of claim 1, characterized in that the tubular structure comprises ingrowth matrix material.
12. The wall structure of claim 1, characterized in that at least a part of the sealant material is hydrolytically degradable.
13. The wall structure of claim 1, characterized in that at least a part of the sealant material is enzymatically degradable.
14. The tubular structure of claim 1, characterized in that the layer of sealant material is a film with a thickness of between about 10-200 μm .
15. The tubular structure of claim 1, characterized in that the layer of sealant material is a film with a thickness of between about 10-50 μm .
16. A method of manufacturing a vascular graft prosthesis having a tubular structure with a wall made of biocompatible porous material, characterized by configuring the porous material as highly porous material and placing a thin spanning layer of sealant material on a portion of the wall which reduces the buildup of natural blood products or other material within portions of the wall and facilitates transmural growth of tissue.

17. The method of claim 16 characterized by the further step of configuring another layer of material on the thin spanning layer of material to form an anti-thrombogenic layer.

18. An improved method of making a vascular graft prosthesis so as to provide improved healing after implant of the prosthesis in a recipient, characterized by providing a vascular graft having a lumen and a luminal wall configured with ingrowth-permissive interstices; and applying a permanent or degradable sealant material to a surface of the luminal wall as a spanning film to maintain separation of blood within the vascular graft and tissue forming the graft luminal wall thereby preventing formation of a natural barrier to tissue ingrowth and to promote healing of tissue through substantially the entire graft wall thickness.

19. An implantable wall structure designed for implant into mammalian tissue, having interconnected wall structure material designed for transmural tissue ingrowth and healing by maintaining tissue ingrowth spaces through the wall thickness of at least about 60 μm ; and further characterized by a thin film of sealant material placed on the wall structure to prevent blood products from clogging the tissue ingrowth spaces and said thin film having a degradable material construction and composition so as to promote desired healing of tissue adjacent to and within the wall structure.

20. A biocompatible graft material suitable for use in a mammalian vascular system, the graft material having a volume, length, width and thickness suitable for shaping into a vascular graft; and said graft material characterized by having at least one high porosity structural material for providing pathways through which transmural tissue growth may occur through the thickness of the graft material; and being further characterized by a sealant material deposited at a graft material location in said thickness to prevent the buildup of natural blood products when in use in a recipient at and adjacent to a first surface of the graft material and to facilitate transmural growth of tissue through a thickness of the graft material.

21. The graft material of claim 20, characterized by having a second structural material adjacent a first surface of the sealant material.

22. The graft material of claim 21 characterized by the second structural material being highly porous.

23. The graft material of claim 20, characterized by having an anti-thrombogenic material adjacent a first surface of the sealant material.

FIG. 1





FIG. 2




FIG. 3




FIG. 4

FIG. 5





FIG. 10



3/5





FIG. 6**FIG. 7****FIG. 8****FIG. 9**

FIG. 11






FIG. 12



5/5

**FIG. 13**

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 02/27113

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L27/50 A61L27/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 851 229 A (DEPREKER JENNIFER ET AL) 22 December 1998 (1998-12-22) column 3, line 50 -column 4, line 15 column 5, line 59 -column 6, line 5 claims 1-5,11 ---	1-4,7,8, 12,13, 16,18,20
X	WO 01 05333 A (MEDTRONIC INC) 25 January 2001 (2001-01-25) cited in the application page 3, line 5 - line 14 page 4, line 3 - line 10 claims 1,4,5,7 ---	1-23
A	US 4 784 659 A (WERNER HEINZ-HELMUT ET AL) 15 November 1988 (1988-11-15) column 2, line 38 - line 62 claims 1-3,8 --- -/--	1-23



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *8* document member of the same patent family

Date of the actual completion of the international search

16 December 2002

Date of mailing of the international search report

27/12/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Heck, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 02/27113

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 495 127 A (UBE INDUSTRIES) 22 July 1992 (1992-07-22) column 3, line 3 - line 25 -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 02/27113

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5851229	A	22-12-1998	AU 4414097 A	02-04-1998
			EP 0941131 A1	15-09-1999
			JP 2001506512 T	22-05-2001
			WO 9810804 A1	19-03-1998

WO 0105333	A	25-01-2001	AU 1631300 A	05-02-2001
			EP 1202683 A1	08-05-2002
			WO 0105333 A1	25-01-2001
			US 2001002444 A1	31-05-2001

US 4784659	A	15-11-1988	DE 3608158 A1	17-09-1987
			AT 66126 T	15-08-1991
			BR 8701135 A	05-01-1988
			CA 1283505 A1	30-04-1991
			DE 3772070 D1	19-09-1991
			DK 127987 A	13-09-1987
			EP 0237037 A2	16-09-1987
			FI 871065 A ,B,	13-09-1987
			GR 3002895 T3	25-01-1993
			JP 1051263 B	02-11-1989
			JP 1563185 C	12-06-1990
			JP 62258666 A	11-11-1987
			MX 165145 B	29-10-1992
			NO 870809 A ,B,	14-09-1987
			US 4902290 A	20-02-1990

EP 0495127	A	22-07-1992	DE 69123344 D1	09-01-1997
			DE 69123344 T2	24-04-1997
			EP 0495127 A1	22-07-1992
			WO 9202195 A1	20-02-1992
			US 5549664 A	27-08-1996

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.